Spoke Chooses T IoT from T-Mobile and Deutsche Telekom to Pave the Way for Safer Cycling
13.7.2022 17:34:00 EEST | Business Wire | Press release
Today, T-Mobile (NASDAQ: TMUS) and Deutsche Telekom (NASDAQ: DTEGY) announced that Spoke, a mobility platform for safety, connectivity and rich rider experiences, will use T IoT to help bicyclists and motorists share the road more safely. T IoT, a comprehensive solution for global IoT connectivity, platform management and support, will power Spoke’s new hardware and software system that delivers near real-time information to bicyclists and motorists on the road, to help them reach their destination safely.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712006196/en/
With T IoT, Spoke aims to improve awareness between bicyclists and motorists worldwide (Graphic: Business Wire)
According to the National Highway Traffic Safety Administration, 78 percent of bicycle accidents happen in urban areas where bicyclists ride near traffic. Spoke is on a journey to shrink those numbers by creating an ecosystem of IoT-connected sensors and cameras to provide bicyclists and motorists with highly accurate and timely alerts that will be delivered over LTE and 5G. This helps ensure that bicycles can “digitally” see cars, and more importantly, that cars can see bicycles.
Consider that there were nearly 50 million bicycles sold last year across the world. Then think about the millions of connected vehicles on roadways across the globe. Right now, the process of connecting vehicles to data requires the time-consuming, cumbersome process of enterprise negotiations with different network operators and IoT platforms. And bicyclists and motorists obviously don’t care how a safety notification is delivered or which jurisdiction they are in, as long as alerts are timely and actionable — because the outcome can oftentimes prevent property damage, injury, or ultimately save a life.
T IoT delivers network connectivity spanning the full range of technologies to support nearly every possible IoT scenario today, and tomorrow — including NB-IoT, LTE-M, LTE, and 5G — making it optimized to help deliver near real-time connectivity at scale, in 188 destinations worldwide.
“T IoT supports the low-latency speed and massive data required to connect Spoke’s global network of hardware and software on the road,” said Jarrett Wendt, CEO, Spoke. “As a result, Spoke will deliver much more than peace of mind for cyclists. It will deliver a world-class user experience with ride-enriching features made just for them — like traffic, navigation, ride and health information. T-Mobile and Deutsche Telekom’s leading innovation makes them the perfect teammate for Spoke’s solutions.”
“Spoke is exactly the kind of customer, innovation, and global application we had in mind when we launched T IoT earlier this year,” said Mishka Dehghan, Senior Vice President, Strategy, Product, and Solutions Engineering, T-Mobile Business Group. “Spoke is looking to leverage IoT and 5G for global good, and with T IoT, they will have one team and solution to manage all their connections around the world — to help the most vulnerable on our roadways by connecting them to the mobility ecosystem around them.”
“The future of our traffic system is based on a robust vehicle-to-everything (C-V2X) ecosystem provided through global cellular 5G connectivity. We are happy to support pioneers like Spoke and help building up a reliable connected system for mobility safety and rich rider experiences through our T IoT global footprint”, said Dennis Nikles, CEO of Deutsche Telekom IoT.
To learn more about T IoT from T-Mobile and Deutsche Telekom, go to: www.t-mobile.com/business/solutions/iot/T IoT-global
For more information about Spoke, visit: www.spokesafety.com
Qualifying service & devices required. Coverage not available in some areas.
About T-Mobile
T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: https://www.t-mobile.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712006196/en/
Contact information
Media Contacts
T-Mobile US, Inc. Media Relations
MediaRelations@t-mobile.com
Investor Relations Contact
T-Mobile US, Inc.
investor.relations@t-mobile.com
https://investor.t-mobile.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom